Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems

Despite Pfizer's high 6.7% dividend yield raising concerns about sustainability, the article argues the dividend is safer than it appears. Management has committed to maintaining the dividend while navigating patent expirations through strategic R&D investments, acquisitions, and partnerships. With a cash-based payout ratio just over 100% and a debt-to-equity ratio of 0.7x, Pfizer has sufficient financial flexibility to support its dividend through current business headwinds.